Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration

Long-term safety and efficacy of ziv-aflibercept in retinal diseases

“…In August 2012, US Food and Drug Administration approved ziv-aflibercept for the treatment of advanced colorectal carcinoma 9 12. Ziv-aflibercept is packaged at the same concentration of 1.25 mg/0.05 mL as 4 and 8 mL vials.…”

“…The dose of ziv-aflibercept used was 1.25 mg, which is 62.5% of the standard dose of 2 mg aflibercept used in VIEW, VIVID and VISTA protocols;9 12 however, in the VIEW trials, 0.5 and 2.0 mg produced quite comparable outcomes 6 9 12…”

“…Macular changes using spectral domain OCT were done monthly using 3D-2000 Topcon FA plus (Topcon, Tokyo, Japan) in Lebanon, Spectralis (Heidelberg Engineering GmbH, Heidelberg, Germany) in Egypt and Cirrus (Carl Zeiss Meditec, Dublin, California) in India. Central macular thickness (CMT) measurements (mean thickness in the central 1000 μm diameter area) were corrected for machine use according to established formulae 9 12. Intraocular pressure was measured using applanation tonometry.…”

“…Chhablani et al 7 detected no electroretinographic alterations 1 month after injection of ziv-aflibercept in eyes with nAMD. Three-month studies in DME8–11 or nAMD12 and case reports13–16 attested to the short-term safety of the drug. However, long-term safety data after multiple injections are still lacking.…”

Effect of Intravitreal Ziv-Aflibercept on Choroidal Neovascularization Membrane Secondary to Post Traumatic Choroidal Rupture

“…Clinical trial conducted by Malik et al [3] to address the safety issue of ziv-aflibercept in vivo and in vitro and concluded that there is non-significant RPE toxicity where, Mansour et al [4] has studied the safety of intravitreal Ziv-aflibercept in six patients and all patients, and the results didn't show any signs of retinal, ocular toxicity or inflammation and suggested that the 0.05 ml Ziv-aflibercept is diluted in 4 ml of vitreous when intravitreally injected, thus it is 80 times diluted which means the final osmolarity of 312 mOsm/kg after intravitreal injection of 0.05 ml Ziv-aflibercept, Masnour et al [5] also studied the safety and efficacy of intravitreal ziv-aflibercept in wet age related macular degeneration and concluded that intravitreal ziv-aflibercept can be safe and effective without causing any ocular toxicity. …”